The company’s first NanoCBD sale offers validation of the product and differentiated delivery technology and points to the global prospects for Medlab developed products. Medlab shares were up 2.33% to 44 cents in today’s trading Medlab Clinical Ltd ( ASX:MDC ) has begun manufacturing its NanoCBD product at a licensed FDA facility after receiving its first export order to Hong Kong for 1,500 units of the cannabinoid product. Australian delivery for use under the Special Access Scheme is expected by Christmas 2019. This is the third cannabinoid product Medlab has produced and like the previous two, it utilises Medlab’s proprietary delivery system NanoCelle and maintains all the rigours of quality in the manufacturing cycle. Other countries that allow CBD from hemp instead of marijuana, specifically the US market, are being investigated with potential partners. “Capabilities of NanoCelle delivery platform” Medlab chief executive officer Sean Hall said: “NanoCBD is another […]